| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | SANGAMO THERAPEUTICS INCORPO | Jul 12, 2024 | |
| Buy | SANGAMO ADR LTD | Dec 13, 2023 | |
| Buy | SANGAMO THERAPEUTICS INC CMN | Aug 23, 2021 | |
| Sell | SANGAMO THERAPEUTICS INC CMN | Apr 20, 2020 | |
| Sell | SANGAMO TECHNOLOGY PLC CMN | Jan 4, 2020 | |
| Buy | SEATTLE GENETICS, INC CMN | Apr 23, 2019 | |
| Sell | SEATTLE GENETICS, INC CMN | Apr 2, 2019 | |
| Buy | Sangamo Therapeutics, Inc. | Jul 20, 2017 | |
| Buy | Sangamo Biosciences | Nov 30, 2016 | |
| Buy | SANGAMO BIOSCIENCES | Mar 2, 2016 |
This page tracks congressional stock trading activity in Sangamo Therapeutics, Inc. (SGMO) in the Healthcare sector. Disclosed Capitol has indexed 12 disclosed congressional trades involving SGMO. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of July 2024 — Disclosed Capitol has tracked 12 disclosed congressional trades in Sangamo Therapeutics, Inc. (SGMO) — 8:4 buy-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Jul 12, 2024 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Dec 13, 2023 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Aug 23, 2021 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Apr 20, 2020 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Jan 4, 2020 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Apr 23, 2019 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Apr 2, 2019 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Jul 20, 2017 | Rodney Frelinghuysen | R | Purchase | $1,001 - $15,000 |
| Nov 30, 2016 | Rodney Frelinghuysen | R | Purchase | $15,001 - $50,000 |
| Mar 2, 2016 | Rodney Frelinghuysen | R | Purchase | $1,001 - $15,000 |
Across the 12 disclosed congressional trades in Sangamo Therapeutics, Inc. (SGMO), members of Congress have reported 8 buys and 4 sells. The average 30-day alpha vs. the S&P 500 is 7.89%.
For fiscal year 2025, Sangamo Therapeutics, Inc. reported revenue of $57.8M and net income of -$97.9M, per SEC filings.
Most recent reported quarter: Q1 FY2026 — revenue $1.4M, net income -$31.0M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.